BELLUS Health, the streamlined and focused drug development company concentrating on rare diseases, yesterday reported Q1 to March 2015 results with a loss of C$46k, vs C$680k in the comparative period helped by royalties from VIVIMINDTM and lower R&D spend in relation to the development of ShigamabTM. On its lead program KIACTATM for AA Amyloidosis, now fully enrolled, the company reported that approximately 75% of the required events to complete Phase III Confirmatory Study have occurre
13 May 2015
Q1 results – losses stemmed, Phase III on track.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1 results – losses stemmed, Phase III on track.
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.53m
- Published:
13 May 2015 -
Author:
Derren Nathan -
Pages:
6
BELLUS Health, the streamlined and focused drug development company concentrating on rare diseases, yesterday reported Q1 to March 2015 results with a loss of C$46k, vs C$680k in the comparative period helped by royalties from VIVIMINDTM and lower R&D spend in relation to the development of ShigamabTM. On its lead program KIACTATM for AA Amyloidosis, now fully enrolled, the company reported that approximately 75% of the required events to complete Phase III Confirmatory Study have occurre